| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Topline Data Readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Topline Data Readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Topline Data Readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
LeonaBio, Inc.$9.6
+0.21 (+2.24%)
D 30Pipeline Score Overvalued Biotech · Clinical
Market Cap
97.03 M
EPS
-24.09
P/E Ratio
-
Value Trade
333.64 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
11.26 M
Operating CF
-20.90 M
Total Assets
71.59 M
Total Liabilities
22.29 M
Equity
49.30 M
D/E Ratio
12,345
-4.53 %
Week
9.54 %
1 Month
87.82 %
3 Month
123.59 %
6 Month
-99.45 %
5 Year
-99.48 %
All Time
Cash Data
Cash Position
67.68 M
Monthly Burn
6.97 M
Runway
7.5 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
39.05 K
52 Week Range
3.60 - 50.74
% held by Insiders
23.36 %
% held by Institutions
48.16 %
Enterprise Value
30.05 M
Total Shares
9.34 M
Short %
0.91 %
Float Shares
6.17 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for LeonaBio, Inc.
169Total events
5Upcoming
31Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 5
2026-H2
T2Trial Initiation
On-track to initiate Phase 2 proof-of-concept study in ALS patients in 2H 2026
Event history 164
Jun 24, 2026
◆Oral PresentationPresentation
Panel presentation at BIO International Convention: The Future of Oncology Trials
oncologysource ↗
Jun 3, 2026
◆Oral PresentationATH-1105Presentation
Oral presentation at 5th Annual ALS Drug Development Summit: Advancing ATH-1105 in ALS
ALSsource ↗
May 5, 2026
▲Management ChangeCorporate
Appointment of Fred Callori, Natalie Holles, and Peter B. Silverman to Board of Directors
Feb 3, 2026
Jan 9, 2026
▲Enrollment UpdatelasofoxifeneTrial
ELAINE-3 trial more than 50% enrolled
metastatic breast cancersource ↗
Jan 9, 2026
▲First Patient DosedATH-1105Trial
First-in-human Phase 1 trial enrolled 80 healthy volunteers
healthy volunteerssource ↗
Q1 2026
◆Trial InitiationATH-1105Trial
Phase 2 trial initiation planned for ATH-1105 in ALS patients
ALSsource ↗
2026
▲Oral PresentationlasofoxifenePresentation
Nonclinical data presented at AACR Annual Meeting 2026 (AACR26)
ER-positive, HER2-negative, ESR1-mutated metastatic breast cancersource ↗
Dec 18, 2025
▲Partnership / LicenselasofoxifeneCorporate
Exclusive global license from Sermonix Pharmaceuticals for lasofoxifene
metastatic breast cancersource ↗
Dec 18, 2025
▼Equity OfferingCorporate
Upfront $90 million private placement financing with potential additional $146 million from warrants
Drug Pipeline Intelligence
D30
Pipeline Score $23M
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.2x
rNPV / MCap Top 35%
Micro Cap (rank 594 of 912)
Percentile RankLeonaBio, Inc. faces pipeline headwinds (30/100), with $468M risk-adjusted pipeline value, led by ATH-1017 in Alzheimer Disease (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATH-1017 Small molecule | Alzheimer Disease | Phase 2 | NCT04491006 | 11% | $193M | COMPLETED | 631 | - | - | May 20, 2022 | - | Jun 12, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ATH-1105 | ALS | Phase 1 | 2025-11-06 | favorable safety profile; well tolerated in both single and multiple ascending dose studies; dose proportional pharmacokinetics; CNS penetration Read More | Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update Continuing to explore strategic alternatives focusing on maximizing stockholder value Presented results from Phase 1 clinical trial Read More | |
ATH-1105 | ALS | Phase 1 | 2025-11-06 | favorable safety profile; well tolerated in both single and multiple ascending dose studies; dose proportional pharmacokinetics; CNS penetration Read More | Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update Continuing to explore strategic alternatives focusing on maximizing stockholder value Presented results from Phase 1 clinical trial Read More | |
ATH-1105 | ALS | Phase 1 | 2025-11-06 | favorable safety profile; well tolerated in both single and multiple ascending dose studies; dose proportional pharmacokinetics; CNS penetration Read More | Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update Continuing to explore strategic alternatives focusing on maximizing stockholder value Presented results from Phase 1 clinical trial Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LONA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LONA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LONALeonaBio to Participate in Upcoming Medical and Industry Meetings in June
LeonaBio, a clinical-stage biopharmaceutical company, will participate in two key industry meetings in June 2026. The first is the 5th Annual ALS Drug Development Summit in Boston, where they will present on their drug ATH-1105. The second is the BIO International Convention in San Diego, focusing on oncology trials and patient survival.
Read more →LONALeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.
LeonaBio, a clinical-stage biopharmaceutical company, has appointed Fred Callori, Natalie Holles, and Peter B. Silverman to its Board of Directors as of May 5, 2026. These appointments are expected to strengthen the company's leadership and align with its focus on developing novel therapeutics for unmet medical needs. The company also acknowledged the retirement of John Fluke, Jr., who served on the board since 2014.
Read more →LONALeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Oppor
LeonaBio, a clinical-stage biopharmaceutical company, reported its first-quarter financial results for 2026 and highlighted its ongoing commitment to developing lasofoxifene, a selective estrogen receptor modulator, for treating metastatic breast cancer with ESR1 mutations. The company expects to complete enrollment in its Phase 3 trial by Q4 2026 and anticipates topline data in the second half of 2027. Additionally, LeonaBio plans to initiate a Phase 2 trial for ATH-1105 targeting ALS patients in the latter half of 2026, with promising results from earlier studies. Recent leadership appointments are also part of the company's strategic focus moving forward.
Read more →LONA▼ -7.3%on this news
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
LeonaBio reported its financial results for 2025, highlighting the acquisition of lasofoxifene, a promising treatment for breast cancer. The company raised $90 million in funding, with the possibility of an additional $146 million. They expect to complete enrollment in a Phase 3 trial by late 2026 and initiate a Phase 2 study for ALS in the same timeframe. Leadership expresses confidence in their evolving pipeline and future milestones.
Read more →LONALeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer
LeonaBio has appointed Mark F. Kubik as Chief Business Officer to lead its business development strategy. Kubik, who has over 25 years of experience in the biopharmaceutical industry, previously served as a strategic consultant for the company. His role will be crucial as LeonaBio advances its Phase 3 development program for lasofoxifene, targeting treatment-resistant metastatic breast cancer.
Read more →LONAJulie.rathbun@leonabio.com 206-769-9219
Athira Pharma has officially changed its name to LeonaBio, Inc. and adopted the new ticker symbol LONA, effective January 12, 2026. This change follows the company's acquisition of rights to develop losofoxifene, a promising drug for the treatment of metastatic breast cancer currently in Phase 3 trials. LeonaBio aims to focus on addressing unmet medical needs through its innovative pipeline, which also includes candidates for neurodegenerative diseases. The company plans to advance its therapies with considerable financial backing and is committed to improving treatment outcomes for patients with serious diseases.
Read more →LONANo presentations available at this time
LONA has announced that there are no presentations or publications available at this time. This lack of available information may raise concerns about the company's current research or development activities. Stakeholders may find this absence of updates disappointing.
Read more →LONAAthira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million Phase 3 Development Program of Novel Selective Estrogen
Athira Pharma has announced an exclusive license for the development of lasofoxifene, a selective estrogen receptor modulator, focused on treating metastatic breast cancer. The company secured $90 million in upfront financing, with potential total financing of $236 million, to support the Phase 3 development program aimed at patients with ESR1 mutations. The ongoing ELAINE-3 clinical trial is already over 50% enrolled, with topline data expected in mid-2027. This development represents a significant opportunity for Athira to enhance its pipeline and potentially shape treatment standards in breast cancer care.
Read more →LONAATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective in co-culture of human iPSC-derived motor neurons and muscle
The article discusses ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, demonstrating neuroprotective properties in co-cultures of human iPSC-derived motor neurons and muscle. This research suggests ATH-1105 could play a significant role in developing therapies for neurodegenerative conditions. The findings emphasize the importance of the HGF system in neuroprotection.
Read more →LONAFosgonimeton in Mild-to-Moderate Alzheimer’s Disease; Efficacy and Safety from the LIFT-AD Trial
The article discusses the efficacy and safety of Fosgonimeton in patients with mild-to-moderate Alzheimer's disease, based on findings from the LIFT-AD trial. Results indicate that Fosgonimeton may offer significant benefits for this patient population, with a favorable safety profile. The study contributes valuable insights into potential treatment options for Alzheimer's disease.
Read more →LONAAthira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update Continuing to explore strategic alternatives focusing on maximizing stockholder value Presented results from Phase 1 clinical trial
Athira Pharma provided its financial results for Q3 2025, highlighting a favorable safety profile for its drug ATH-1105 in a Phase 1 clinical trial targeting ALS. The company is exploring strategic alternatives to maximize shareholder value amidst ongoing clinical developments. Athira reported a net loss of $6.6 million for the quarter and decreased cash reserves, raising potential concerns about funding future initiatives. However, the positive trial results suggest a promising future for ATH-1105 in the treatment of neurodegenerative diseases.
Read more →LONAAthira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proport
Athira Pharma reported its second quarter 2025 financial results, highlighting positive data from its Phase 1 trial of ATH-1105. The trial exhibited a favorable safety profile and dose proportional pharmacokinetics, supporting the drug's continued development for ALS. However, Athira is exploring strategic alternatives due to the underperformance of its previous drug candidate and decreasing cash reserves. The CEO expressed optimism regarding the future plans for ATH-1105 and aims to initiate subsequent trials in ALS patients soon.
Read more →LONAAthira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS)
Athira Pharma reported its first quarter 2025 financial results, highlighting the completion of a Phase 1 clinical study for ATH-1105, a potential treatment for ALS. The study demonstrated a favorable safety profile and is expected to allow dosing in ALS patients by late 2025. The company is also exploring strategic alternatives following setbacks with its Alzheimer’s treatment candidate, fosgonimeton. Financially, Athira experienced a loss but has made cuts in R&D expenses.
Read more →LONAEffects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients with ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study
The ELAINE 1 study investigates the effects of Lasofoxifene versus Fulvestrant on vaginal and vulvar symptoms in patients with ESR1-mutated, ER+/HER2- metastatic breast cancer. The findings suggest that Lasofoxifene may offer significant benefits in managing these symptoms, providing a new therapeutic option for this patient population. This research highlights the importance of addressing quality of life issues in cancer treatment.
Read more →LONAAthira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS) On-
Athira Pharma, Inc. reported financial results for 2024 along with updates on its pipeline. The Phase 1 clinical study of ATH-1105, aimed at treating ALS, was completed successfully, showing a favorable safety profile. The company plans to start dosing ALS patients by 2025 based on preclinical improvements seen in nerve and motor function. However, development of another candidate, fosgonimeton, has been paused following the LIFT-AD trial results, which did not meet its endpoints. Athira is exploring strategic alternatives to maximize stockholder value.
Read more →LONAAthira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025
Athira Pharma reported its financial results for Q3 2024 and provided updates on its clinical pipeline, particularly focusing on ATH-1105, a drug candidate for ALS. The company expects to complete Phase 1 trials of ATH-1105 by the end of 2024 and plans to start dosing ALS patients in 2025. Despite a strong pipeline, the company faced challenges as its Alzheimer's drug candidate, fosgonimeton, did not meet key trial endpoints and is currently put on hold. Financially, Athira reported a net loss of $28.7 million for the quarter.
Read more →LONAELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1-mutated, metastatic breast cancer
The ELAINE 3 study is a Phase 3 clinical trial investigating the efficacy of lasofoxifene combined with abemaciclib for treating ER+/HER2-, ESR1-mutated metastatic breast cancer. This research aims to provide new therapeutic options for patients with this specific cancer subtype. The study highlights the ongoing efforts to address unmet medical needs in oncology.
Read more →LONAAthira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical
Athira Pharma has announced a strategic focus on advancing ATH-1105, an orally administered drug, for treating neurodegenerative diseases, particularly ALS and Alzheimer's. The company is implementing cost containment measures including a workforce reduction, which will help extend its cash runway into early 2026. ATH-1105 has demonstrated promising preclinical results, suggesting neuroprotective benefits, while the ongoing Phase 1 clinical trial aims to assess its safety and tolerability. The company also acknowledges potential risks ahead, including regulatory approvals and recruitment for clinical studies.
Read more →LONAAthira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease     LIFT-AD trial did not meet primary endpoint of GST and key secondar
Athira Pharma reported topline results from its Phase 2/3 LIFT-AD trial evaluating fosgonimeton for mild-to-moderate Alzheimer's disease. While the trial did not meet its primary or key secondary endpoints, pre-specified subgroup analyses suggested potential benefits in certain patient groups. Biomarker data indicated improvements consistent with the drug's neuroprotective actions. Despite these encouraging findings, the overall clinical significance was not demonstrated, leading to challenges in interpreting fosgonimeton's efficacy.
Read more →LONAAthira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates Topline data from completed Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alz
Athira Pharma reported its Q2 2024 financial results and provided updates on its clinical pipeline. The company is anticipating topline data from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton for mild-to-moderate Alzheimer's disease, expected by September 2024. Positive preclinical data suggest fosgonimeton's potential to mitigate Alzheimer's pathology, while a Phase 1 trial for ALS treatment (ATH-1105) is underway. However, Athira faces financial challenges, with a reported net loss and declining cash reserves.
Read more →LONAAthira Pharma Announces Proposed Settlement of Stockholder Derivative Action BOTHELL, WA
Athira Pharma has announced the preliminary approval of a proposed settlement related to stockholder derivative actions against certain individuals. This settlement requires Athira to implement corporate governance reforms and cover legal fees associated with the litigation. A final approval hearing is scheduled for July 18, 2024. This move aims to resolve prior legal disputes and could enhance the company’s governance structure, positively impacting investor confidence.
Read more →LONAAthira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's di
Athira Pharma has reported its Q1 2024 financial results and updates on its pipeline, particularly focusing on the LIFT-AD clinical trial for its candidate fosgonimeton aimed at treating mild-to-moderate Alzheimer's disease. The company anticipates topline data from the trial in the second half of 2024, which could be a significant milestone in Alzheimer's treatment. Additionally, it has submitted an IND application for ATH-1105, targeting amyotrophic lateral sclerosis (ALS), with a first-in-human study expected to commence in Q2 2024. The company emphasized its robust financial position, which facilitates its innovative drug development efforts.
Read more →LONAPalazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
Palazestrant (OP-1250) has been shown to effectively inhibit both wild-type and mutant estrogen receptor-positive breast cancer models. This complete estrogen receptor antagonist demonstrates potential as both a standalone treatment and in combination therapies, marking a significant advancement in breast cancer treatment options.
Read more →LONAAthira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates Enrollment completed in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's
Athira Pharma reported its full-year financial results for 2023 and provided updates on its clinical pipeline. Enrollment in the Phase 2/3 LIFT-AD trial for fosgonimeton, targeting mild-to-moderate Alzheimer's disease, has been completed, with topline data expected in the second half of 2024. The company is also set to initiate first-in-human studies of ATH-1105 for ALS in the first half of 2024. Additionally, Athira continues to highlight its strong financial standing to support ongoing developments.
Read more →LONAAthira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update Completed enrollment in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease and exp
Athira Pharma has completed enrollment in its Phase 2/3 LIFT-AD clinical trial, evaluating fosgonimeton for mild-to-moderate Alzheimer's disease, with topline results expected in late 2024. The company plans to initiate first-in-human studies of ATH-1105 for amyotrophic lateral sclerosis in the first half of 2024. Additionally, the company reported encouraging data from the SHAPE Phase 2 trial regarding cognitive improvements in Parkinson's disease dementia. Athira's financial position remains strong with approximately $147.4 million in reserves to support ongoing and upcoming studies.
Read more →LONALasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial
The ELAINE 1 trial evaluated lasofoxifene versus fulvestrant in patients with ER+/HER2- metastatic breast cancer harboring an ESR1 mutation. Results indicate that lasofoxifene may offer a beneficial alternative treatment option. This randomized phase II trial highlights the importance of targeted therapies in specific cancer subtypes.
Read more →LONAOpen-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2
The ELAINE 2 study is an open-label, phase II trial investigating the efficacy of lasofoxifene combined with abemaciclib in women with metastatic ER+/HER2- breast cancer who have an ESR1 mutation. This study targets patients who have experienced disease progression after previous therapies. The multicenter design aims to provide comprehensive data on this treatment approach.
Read more →LONAAthira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates Continues to report clinical and preclinical findings supporting the potential benefits of its small molecule therapeutic candi
Athira Pharma reported its financial results for Q3 2023, highlighting ongoing positive clinical and preclinical findings for its therapeutic candidates targeting the neurotrophic HGF system. The company is preparing to complete enrollment for the Phase 2/3 LIFT-AD trial of its candidate fosgonimeton in Alzheimer's patients by early 2024, with expected topline data later in the year. Athira emphasizes its robust financial health and sustained focus on innovative treatments for neurodegenerative diseases, with upcoming presentations to further bolster its data portfolio.
Read more →LONAAthira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates Completed end of Phase 2 meeting and continued engagement with U.S. Food and Drug Administration Appointed Andrew Gengos as Ch
Athira Pharma reported its second quarter financial results, highlighting a strong cash position of $196.3 million and advancements in its therapeutic pipeline, particularly for Alzheimer's disease and ALS. The company successfully completed an end of Phase 2 meeting with the FDA, aligning on key aspects of its fosgonimeton program. While the ongoing LIFT-AD trial shows promise, Athira faces risks, including a net loss of $29.6 million and rising R&D expenses. The appointment of Andrew Gengos as CFO aims to bolster strategic direction amid these challenges.
Read more →LONAAthira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer Veteran biopharmaceutical executive brings over 30 years of financial, corporate strategy, transactional and business development
Athira Pharma has appointed Andrew Gengos as its new Chief Financial Officer and Chief Business Officer, succeeding Glenna Mileson. Gengos brings over 30 years of experience in financial management and corporate strategy, with a background in the life sciences and biotechnology sectors. The company anticipates that his leadership will help advance their goal of developing treatments for neurodegenerative diseases. Gengos expressed excitement about joining the team and addressing the therapeutic potential of their platform technology.
Read more →LONAAthira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer's disease to focus on 40 mg dose Open label exten
Athira Pharma reported its financial results for Q1 2023 and provided updates on its pipeline, particularly focusing on the Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer's disease. The trial will prioritize a 40 mg dosing strategy based on positive data, suggesting its potential for regulatory approval. Additionally, preclinical results for ATH-1105 indicate its efficacy as a treatment for amyotrophic lateral sclerosis (ALS). Financially, the company maintains a strong balance sheet to support future developments.
Read more →LONAAthira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates On track to complete enrollment in Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer's disease in mid-2
Athira Pharma announced its financial results for 2022 and provided updates on its pipeline, highlighting that it is on track to complete the enrollment of the Phase 2/3 LIFT-AD trial for the Alzheimer's drug fosgonimeton by mid-2023. The company reported a strong balance sheet to support ongoing innovation in neurodegenerative disease therapies. However, it also faced financial challenges, including a significant net loss and pending legal settlement costs related to a class action suit. Positive data has encouraged the continued development of its drug candidates like ATH-1105 for ALS.
Read more →LONAAthira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates Independent, unblinded, interim efficacy and futility analysis of Phase 2/3 LIFT-AD study in mild-to-moderate Alzheimer
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates Independent, unblinded, interim efficacy and futility analysis of Phase 2/3 LIFT-AD study in mild-to-moderate Alzheimer's disease patients supports potential clinically meaningfu
Read more →LONAAthira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Patients Following Independent, Unblinded Interim Analysis Results support potential clinically meaningful activity
Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Patients Following Independent, Unblinded Interim Analysis Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate pro
Read more →LONAAthira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates Presented clinical and preclinical data at Alzheimer's Association International Conference 2022 Strong balance sheet
Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates Presented clinical and preclinical data at Alzheimer's Association International Conference 2022 Strong balance sheet to support clinical development pipeline BOTHELL, WA, Aug
Read more →LONAAthira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease Primary endpoint of change in biomarker ERP P300 latency was not statistically si
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease Primary endpoint of change in biomarker ERP P300 latency was not statistically significant for the full study population as combination of f
Read more →LONAAthira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates On track to report topline data from ACT-AD Phase 2 Alzheimer's disease study by end of 2Q22 BOTHELL, WA
Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates On track to report topline data from ACT-AD Phase 2 Alzheimer's disease study by end of 2Q22 BOTHELL, WA, May 12, 2022 Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stag
Read more →LONAAthira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update On track to report topline data from ACT-AD Phase 2 Alzheimer's disease study in 2Q22 Expect to complete enrollment in LIFT-AD Phase 3 A
Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update On track to report topline data from ACT-AD Phase 2 Alzheimer's disease study in 2Q22 Expect to complete enrollment in LIFT-AD Phase 3 Alzheimer's disease study in 3Q22 Conference call today at
Read more →LONAAthira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors Industry Veteran Brings More than 20 Years of Experience in CNS Drug Development and Commericalization
Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors Industry Veteran Brings More than 20 Years of Experience in CNS Drug Development and Commericalization BOTHELL, Wash., March 21, 2022 Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stag
Read more →LONAAthira Pharma Announces Appointment of Grant Pickering to its Board of Directors
Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors BOTHELL, Wash., January 31, 2022 Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurod
Read more →LONAAthira Pharma Reports Third Quarter 2021 Financial Results and Business Update – Completed enrollment of ACT-AD trial with topline data expected in the first half of 2022; LIFT-AD is actively recruiting with topli
Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update Completed enrollment of ACT-AD trial with topline data expected in the first half of 2022; LIFT-AD is actively recruiting with topline data expected by the end of 2022 Presented program updates and b
Read more →LONAAthira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer Special Committee of the Board of Directors has c
Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief BOTHELL, WA, October 21, 2021 Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on
Read more →LONAAthira Pharma Reports Second Quarter 2021 Financial Results and Business Update -Initiated open label extension for LIFT-AD and ACT-AD trials of ATH-1017 allowing for an additional six months of treatment - ACT-AD and LI
Athira Pharma Reports Second Quarter 2021 Financial Results and Business Update -Initiated open label extension for LIFT-AD and ACT-AD trials of ATH-1017 allowing for an additional six months of treatment - ACT-AD and LIFT-AD are actively recruiting; topline data of ACT-AD are
Read more →LONAAthira Pharma Mourns the Loss of Chair of Board of Directors, Tadataka Yamada
Athira Pharma Mourns the Loss of Chair of Board of Directors, Tadataka Yamada, M.D. August 5, 2021 Athira Pharma, Inc. (NASDAQ: ATHA) ( Athira ), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegen
Read more →LONAAthira Pharma Chief Operating Officer, Mark Litton, Assumes Day-to-Day Leadership Responsibilities of Company Leen Kawas Placed on Temporary Leave Pending Board Review of Actions Stemming from Doctoral Research while at
Athira Pharma Chief Operating Officer, Mark Litton, Assumes Day-to-Day Leadership Responsibilities of Company Leen Kawas Placed on Temporary Leave Pending Board Review of Actions Stemming from Doctoral Research while at Washington State University BOTHELL, WASHINGTON, June 17,
Read more →LONAAthira Pharma Reports First Quarter 2021 Financial Results and Provides Business Highlights -Phase 2 trial initiation for Parkinson's disease dementia program and IND submission for neuropsychiatric program planned by en
Athira Pharma Reports First Quarter 2021 Financial Results and Provides Business Highlights -Phase 2 trial initiation for Parkinson's disease dementia program and IND submission for neuropsychiatric program planned by end of 2021- -Hosted educational webinar on targeting HGF/ME
Read more →LONAAthira Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights - LIFT-AD and ACT-AD studies evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-
Athira Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights BOTHELL, WA. March 25, 2021 - Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal
Read more →LONAAthira Pharma Announces Appointment of Barbara Kosacz to its Board of Directors BOTHELL, WASHINGTON
Athira Pharma Announces Appointment of Barbara Kosacz to its Board of Directors BOTHELL, WASHINGTON, March 8, 2021 - Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neu
Read more →LONAThis presentation and the accompanying oral commentary contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our mana
This presentation and the accompanying oral commentary contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our management's beliefs and assumptions and on information currentl
Read more →LONAAthira Pharma Announces Appointment of Kelly A. Romano to its Board of Directors SEATTLE
Athira Pharma Announces Appointment of Kelly A. Romano to its Board of Directors SEATTLE, Dec. 14, 2020 - Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegenerat
Read more →LONAAthira Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights - LIFT-AD clinical trial evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer'
Athira Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights - LIFT-AD clinical trial evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer's disease, actively enrolling - Strong cash, cash equivale
Read more →Competitive Position
How LONA ranks across every disease it competes inCompetitive Position is a premium feature
See how LONA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial